Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C. Byrd, Wojciech Jurczak, Susan O’Brien et al.|Journal of Clinical Oncology|2021Cited by 630
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 <sup>+</sup> Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic LeukemiaJean‐Baptiste Robin, Thibaut Leguay, Marc Delord et al.|Journal of Clinical Oncology|2024Cited by 33
Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO StudyPatrice Chevallier, Philippe Rousselot, Thibault Leguay et al.|Blood|2022Cited by 32
Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantationLudovic Lhermitte, Rathana Kim, Nicolas Boissel et al.|Leukemia|2020Cited by 27